Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma

Jens Bedke; Laurence Albiges; Umberto Capitanio; Rachel H. Giles; Milan Hora; Thomas B. Lam; Börje Ljungberg; Lorenzo Marconi; Tobias Klatte; Alessandro Volpe; Yasmin Abu-Ghanem; Saeed Dabestani; Sergio Fernández-Pello; Fabian Hofmann; Teele Kuusk; Rana Tahbaz; Thomas Powles; Axel Bex

doi:10.1016/j.eururo.2020.12.005

Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma

Jens Bedke, Laurence Albiges, Umberto Capitanio, Rachel H. Giles, Milan Hora, Thomas B. Lam, Börje Ljungberg, Lorenzo Marconi, Tobias Klatte, Alessandro Volpe, Yasmin Abu-Ghanem, Saeed Dabestani, Sergio Fernández-Pello, Fabian Hofmann, Teele Kuusk, Rana Tahbaz, Thomas Powles, Axel Bex

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

98 Citations (Scopus)

Résumé

Longer follow-up and new trial data from phase 3 randomised controlled trials investigating immune checkpoint blockade (PD-1 or its ligand PD-L1) in advanced clear-cell renal cell carcinoma (RCC) have recently become available. The CheckMate 9ER trial demonstrated an improved progression-free survival (PFS) and overall survival (OS) benefit for the combination of cabozantinib plus nivolumab. A Keynote-426 update demonstrated an ongoing OS benefit for pembrolizumab plus axitinib in the intention-to-treat population, with a PFS benefit seen across all International Metastatic Database Consortium (IMDC) subgroups, while an update of CheckMate 214 confirmed the long-term benefit of ipilimumab plus nivolumab in IMDC intermediate and poor risk patients. The RCC Guidelines Panel continues to recommend these tyrosine kinase inhibitors + immunotherapy (IO) combination across IMDC risk groups in advanced first-line RCC and dual immunotherapy of ipilimumab and nivolumab in IMDC intermediate and poor risk. Patient summary: New data from trials of immune checkpoint inhibitors for advanced kidney cancer confirm a survival benefit with the combination of cabozantinib plus nivolumab and pembrolizumab plus axitinib and ipilimumab plus nivolumab. These combination therapies are recommended as first-line treatment for advanced kidney cancer.

langue originale	Anglais
Pages (de - à)	339-342
Nombre de pages	4
journal	European Urology
Volume	79
Numéro de publication	3
Les DOIs	https://doi.org/10.1016/j.eururo.2020.12.005
état	Publié - 1 mars 2021

Accès au document

10.1016/j.eururo.2020.12.005

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Bedke, J., Albiges, L., Capitanio, U., Giles, R. H., Hora, M., Lam, T. B., Ljungberg, B., Marconi, L., Klatte, T., Volpe, A., Abu-Ghanem, Y., Dabestani, S., Fernández-Pello, S., Hofmann, F., Kuusk, T., Tahbaz, R., Powles, T., & Bex, A. (2021). Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma. European Urology, 79(3), 339-342. https://doi.org/10.1016/j.eururo.2020.12.005

@article{7824b03c533b436cb32b8c4211a2fc66,

title = "Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-na{\"i}ve Metastatic Clear-Cell Renal Cell Carcinoma",

abstract = "Longer follow-up and new trial data from phase 3 randomised controlled trials investigating immune checkpoint blockade (PD-1 or its ligand PD-L1) in advanced clear-cell renal cell carcinoma (RCC) have recently become available. The CheckMate 9ER trial demonstrated an improved progression-free survival (PFS) and overall survival (OS) benefit for the combination of cabozantinib plus nivolumab. A Keynote-426 update demonstrated an ongoing OS benefit for pembrolizumab plus axitinib in the intention-to-treat population, with a PFS benefit seen across all International Metastatic Database Consortium (IMDC) subgroups, while an update of CheckMate 214 confirmed the long-term benefit of ipilimumab plus nivolumab in IMDC intermediate and poor risk patients. The RCC Guidelines Panel continues to recommend these tyrosine kinase inhibitors + immunotherapy (IO) combination across IMDC risk groups in advanced first-line RCC and dual immunotherapy of ipilimumab and nivolumab in IMDC intermediate and poor risk. Patient summary: New data from trials of immune checkpoint inhibitors for advanced kidney cancer confirm a survival benefit with the combination of cabozantinib plus nivolumab and pembrolizumab plus axitinib and ipilimumab plus nivolumab. These combination therapies are recommended as first-line treatment for advanced kidney cancer.",

keywords = "Cabozantinib, Clear cell, First line, Nivolumab, Renal cell carcinoma, Systemic therapy, Treatment-na{\"i}ve",

author = "Jens Bedke and Laurence Albiges and Umberto Capitanio and Giles, {Rachel H.} and Milan Hora and Lam, {Thomas B.} and B{\"o}rje Ljungberg and Lorenzo Marconi and Tobias Klatte and Alessandro Volpe and Yasmin Abu-Ghanem and Saeed Dabestani and Sergio Fern{\'a}ndez-Pello and Fabian Hofmann and Teele Kuusk and Rana Tahbaz and Thomas Powles and Axel Bex",

note = "Publisher Copyright: {\textcopyright} 2020 European Association of Urology",

year = "2021",

month = mar,

day = "1",

doi = "10.1016/j.eururo.2020.12.005",

language = "English",

volume = "79",

pages = "339--342",

journal = "European Urology",

issn = "0302-2838",

number = "3",

}

Bedke, J, Albiges, L, Capitanio, U, Giles, RH, Hora, M, Lam, TB, Ljungberg, B, Marconi, L, Klatte, T, Volpe, A, Abu-Ghanem, Y, Dabestani, S, Fernández-Pello, S, Hofmann, F, Kuusk, T, Tahbaz, R, Powles, T & Bex, A 2021, 'Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma', European Urology, VOL. 79, Numéro 3, p. 339-342. https://doi.org/10.1016/j.eururo.2020.12.005

Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma. / Bedke, Jens; Albiges, Laurence; Capitanio, Umberto et al.
Dans: European Urology, Vol 79, Numéro 3, 01.03.2021, p. 339-342.

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

TY - JOUR

T1 - Updated European Association of Urology Guidelines on Renal Cell Carcinoma

T2 - Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma

AU - Bedke, Jens

AU - Albiges, Laurence

AU - Capitanio, Umberto

AU - Giles, Rachel H.

AU - Hora, Milan

AU - Lam, Thomas B.

AU - Ljungberg, Börje

AU - Marconi, Lorenzo

AU - Klatte, Tobias

AU - Volpe, Alessandro

AU - Abu-Ghanem, Yasmin

AU - Dabestani, Saeed

AU - Fernández-Pello, Sergio

AU - Hofmann, Fabian

AU - Kuusk, Teele

AU - Tahbaz, Rana

AU - Powles, Thomas

AU - Bex, Axel

PY - 2021/3/1

Y1 - 2021/3/1

N2 - Longer follow-up and new trial data from phase 3 randomised controlled trials investigating immune checkpoint blockade (PD-1 or its ligand PD-L1) in advanced clear-cell renal cell carcinoma (RCC) have recently become available. The CheckMate 9ER trial demonstrated an improved progression-free survival (PFS) and overall survival (OS) benefit for the combination of cabozantinib plus nivolumab. A Keynote-426 update demonstrated an ongoing OS benefit for pembrolizumab plus axitinib in the intention-to-treat population, with a PFS benefit seen across all International Metastatic Database Consortium (IMDC) subgroups, while an update of CheckMate 214 confirmed the long-term benefit of ipilimumab plus nivolumab in IMDC intermediate and poor risk patients. The RCC Guidelines Panel continues to recommend these tyrosine kinase inhibitors + immunotherapy (IO) combination across IMDC risk groups in advanced first-line RCC and dual immunotherapy of ipilimumab and nivolumab in IMDC intermediate and poor risk. Patient summary: New data from trials of immune checkpoint inhibitors for advanced kidney cancer confirm a survival benefit with the combination of cabozantinib plus nivolumab and pembrolizumab plus axitinib and ipilimumab plus nivolumab. These combination therapies are recommended as first-line treatment for advanced kidney cancer.

AB - Longer follow-up and new trial data from phase 3 randomised controlled trials investigating immune checkpoint blockade (PD-1 or its ligand PD-L1) in advanced clear-cell renal cell carcinoma (RCC) have recently become available. The CheckMate 9ER trial demonstrated an improved progression-free survival (PFS) and overall survival (OS) benefit for the combination of cabozantinib plus nivolumab. A Keynote-426 update demonstrated an ongoing OS benefit for pembrolizumab plus axitinib in the intention-to-treat population, with a PFS benefit seen across all International Metastatic Database Consortium (IMDC) subgroups, while an update of CheckMate 214 confirmed the long-term benefit of ipilimumab plus nivolumab in IMDC intermediate and poor risk patients. The RCC Guidelines Panel continues to recommend these tyrosine kinase inhibitors + immunotherapy (IO) combination across IMDC risk groups in advanced first-line RCC and dual immunotherapy of ipilimumab and nivolumab in IMDC intermediate and poor risk. Patient summary: New data from trials of immune checkpoint inhibitors for advanced kidney cancer confirm a survival benefit with the combination of cabozantinib plus nivolumab and pembrolizumab plus axitinib and ipilimumab plus nivolumab. These combination therapies are recommended as first-line treatment for advanced kidney cancer.

KW - Cabozantinib

KW - Clear cell

KW - First line

KW - Nivolumab

KW - Renal cell carcinoma

KW - Systemic therapy

KW - Treatment-naïve

UR - http://www.scopus.com/inward/record.url?scp=85099364654&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2020.12.005

DO - 10.1016/j.eururo.2020.12.005

M3 - Article

C2 - 33357997

AN - SCOPUS:85099364654

SN - 0302-2838

VL - 79

SP - 339

EP - 342

JO - European Urology

JF - European Urology

IS - 3

ER -